Alzheimer's disease (AD) is the only leading cause of death for which no diseasemodifying therapy is currently available. Recent disappointing trial results at the dementia stage of AD have raised multiple questions about our current approaches to the development of disease-modifying agents. Converging evidence suggests that the pathophysiological process of AD begins many years before the onset of dementia. So why do we keep testing drugs aimed at the initial stages of the disease process in patients at the end-stage of the illness?
|Original language||English (US)|
|Journal||Science translational medicine|
|State||Published - Nov 30 2011|
ASJC Scopus subject areas